Krystal Biotech
KRYS
245 hedge funds and large institutions have $5.24B invested in Krystal Biotech in 2024 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 100 increasing their positions, 71 reducing their positions, and 40 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 71
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
30% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 40
29% more call options, than puts
Call options by funds: $54.5M | Put options by funds: $42.2M
17% more capital invested
Capital invested by funds: $4.49B → $5.24B (+$750M)
10.68% more ownership
Funds ownership: 89.22% → 99.89% (+11%)
5% more funds holding
Funds holding: 234 → 245 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$360M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$131M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$65.2M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$39.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$81.8M |
| 2 |
Jennison Associates
New York
|
-$25.2M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$20.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.8M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SRL
276
Scientech Research LLC
Jersey City,
New Jersey
| – | -$243K | -1,367 | Closed |
|
277
Group One Trading
Chicago,
Illinois
| – | -$200K | -1,192 | Closed |
|
|
MLICM
278
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$202K | -1,136 | Closed |
|
|
ACM
279
Aquatic Capital Management
Chicago,
Illinois
| – | -$178K | -1,000 | Closed |
|
|
CFM
280
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$71.2K | -400 | Closed |
|
|
ACM
281
ADAR1 Capital Management
Austin,
Texas
| – | -$53.4K | -300 | Closed |
|
|
IA
282
IFP Advisors
Tampa,
Florida
| – | -$47.3K | -267 | Closed |
|
|
QT
283
Quantbot Technologies
New York
| – | -$24.4K | -137 | Closed |
|
|
FHA
284
First Horizon Advisors
Memphis,
Tennessee
| – | -$4.27K | -24 | Closed |
|
|
TFM
285
TFC Financial Management
Boston,
Massachusetts
| – | -$178 | -1 | Closed |
|
KRYS Hedge Fund Activity: Q2 2024 in Review
245 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2024, worth a combined $5.24B — up 17% from $4.49B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new KRYS positions and 40 closed out — a net gain of 12 holders — while 100 added to existing stakes and 71 trimmed.
The largest buyer was BlackRock, adding an estimated $360M. The largest seller was Redmile Group, cutting an estimated $81.8M.
- 245 institutional investors held Krystal Biotech (KRYS) as of Q2 2024, up from 234 in Q1 2024.
- Funds reported $5.24B of Krystal Biotech stock for Q2 2024, up 17% quarter-over-quarter.
- 52 funds opened new Krystal Biotech positions in Q2 2024 and 40 closed out, a net change of +12 holders.
- The largest Krystal Biotech buyer in Q2 2024 was BlackRock, an estimated $360M added.
- The largest Krystal Biotech seller in Q2 2024 was Redmile Group, an estimated $81.8M sold.
Based on aggregated 13F filings for Q2 2024.